Johnson & Johnson (JNJ)
NYSE · Healthcare · analysed October 12, 2026
Founded in 1886, Johnson & Johnson is a global healthcare company operating across two core segments: Innovative Medicine, which develops therapies in oncology, immunology, neuroscience, and cardiovascular health, and MedTech, which produces advanced medical devices and surgical technologies. Following the 2023 separation of its consumer health business, Kenvue, the company refocused its strategy entirely on higher-growth, science-driven sectors. Its current priorities include expanding high-margin therapeutic pipelines, executing targeted acquisitions in cardiovascular technology and biotechnology, advancing surgical robotics, and optimizing its portfolio through strategic restructurings.
Executive summary
Johnson & Johnson demonstrates robust commercial execution and exceptional financial strength, backed by 94.19 billion dollars in revenue, a 28.5% net margin, and 19.70 billion dollars in free cash flow1,2. The company is actively executing a strategic pivot toward higher-margin Innovative Medicine and cardiovascular MedTech while advancing late-stage pipeline assets such as icotrokinra and nipocalimab to counter biosimilar erosion on Stelara6,8,9. However, with the stock up 38.9% over the past year and trading at 22.1 times forward earnings, near-term upside appears balanced against a 2027 patent cliff and ongoing Medicare pricing pressures1,6.
The full analysis adds sections on competition, financials and valuation, recent news, upcoming catalysts, institutional investors and fund letters. See the plans or join the waitlist.